retatrutide peptide clinical trial results Phase 3: TRIUMPH Program 2026 Eli Lilly's Phase 3 clinical

Others tolerate the drug but, once meaningful weight reduction is achieved, do not wish to stay on the medication for life

Whilst generally well-tolerated, like all medications, GLP-1 agonists carry potential side effects that patients and healthcare professionals should understand, including concerns about pancreatic safety that warrant careful consideration

The gradual titration made the process feel manageablenever overwhelmingand reinforced that she wasnt navigating this journey alone

Profiles of the Common GLP-1 Receptor Agonists Note: All may cause significant/severe GI symptoms including nausea, vomiting, retching, gastroparesis, abdominal bloating, and pain

www.pendulumlife.com Media Contact: Alafair Hall [email protected] 415-730-9044 SOURCE Pendulum Therapeutics

To counter such impacts, some companies are exploring ways that GLP-1RA drugs could complement their existing solutions